WuXi AppTec
United States
About WuXi AppTec
126 articles about WuXi AppTec
-
Three Biopharma firms disclosed concerns about how emerging geopolitical tensions between the U.S. and China might impact their business with the contract manufacturer.
-
Alongside the abrupt departure of Chinese biotech WuXi from BIO, Congress is rattling sabers over perceived national security implications of the U.S.’s R&D relationship with the country.
-
U.S. intelligence officials have informed senators that China-based biotech WuXi AppTec transferred an American client’s intellectual property to the Chinese government without consent, reports Reuters.
-
In a change of position as congressional scrutiny of WuXi AppTec grows, the Biotechnology Innovation Organization announced it is taking steps to separate from the China-based biotech.
-
WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan
11/9/2023
WuXi AppTec received the 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan, a growth advisory & growth opportunity analytics firm.
-
WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022
4/24/2023
WuXi AppTec is pleased to announce its financial results for the first quarter ending March 31, 2023.
-
WuXi AppTec Reports Record Results in 2022
3/20/2023
WuXi AppTec is pleased to announce its annual results for the year ending December 31, 2022.
-
WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion
10/26/2022
WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the third quarter and nine months ended September 30, 2022 ("Reporting Period").
-
WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation
7/19/2022
WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced a plan to build a new R&D and manufacturing site in Singapore.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Orbit Discovery and WuXi AppTec Sign Agreement to Access Peptide Discovery and Optimisation Technologies
3/7/2022
Orbit Discovery, a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry.
-
WuXi AppTec Reports Strong Third-Quarter 2021 Results
10/29/2021
WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies worldwide in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the third quarter and nine months ended September 30, 2021.
-
WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland
8/3/2021
WuXi STA – a subsidiary of WuXi AppTec – today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland from Bristol Myers Squibb.
-
WuXi STA’s Jinshan Facility Passes EMA Inspection
10/28/2019
STA Pharmaceutical Co., Ltd., – a subsidiary of WuXi AppTec – announced today that its Jinshan manufacturing facility in Shanghai, China has successfully passed an inspection by the European Medicines Agency with no critical and no major findings.
-
WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections
7/23/2019
This not only marks a milestone for WuXi STA on running a continual state of regulatory readiness, with real time GMP monitoring and an ingrained internal quality culture, but also shows its commitment on providing integrated R&D and manufacturing services with the highest quality standard for customers.
-
Chinese companies that gain toeholds in the U.S. are poaching executives from U.S. companies who have significant clinical and regulatory experience.
-
Phoenix Molecular Designs and WuXi STA Reach Drug Supply Milestone to Support Phase I/Ib Study of PMD-026 for TNBC
6/4/2019
Collaboration opens drug product operations in San Diego, CA to support manufacture of RSK inhibitor
-
Altasciences and WuXi AppTec Enter Into Collaboration for WIND Projects
5/16/2019
WuXi Clinical, the clinical CRO arm of WuXi AppTec, will be responsible for managing the partnership and ensuring a seamless experience.
-
SAMDI Tech Provides 1+ Million Compounds Through WuXi Partnership for Drug Candidate Screening
2/26/2019
SAMDI Tech Inc., the industry’s leading provider of label-free drug discovery solutions, now has well over 1 million compounds in its small molecule screening collection, in part through a partnership with WuXi AppTec’s LabNetwork, a global e-commerce platform connecting chemistry and research communities worldwide.
-
Across parts of Europe, Asia and the rest of the globe, pharma and biotech companies have made strides and deals to advance their pipelines and technologies this week.